EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Utility of combined CD39 / CD73 / CD38 expression for the detection of malignant T cells in Sézary syndrome

Sara Marchisio iD, Yuliya Yakymiv iD, Liyun Lin iD, Erika Ortolan iD, Verdiana Pullano iD, Renata Ponti, Fenna J de Bie iD, Alita J van der Sluijs-Gelling, Willem H Zoutman iD, Valentina Pala iD, Ferenc A Scheeren iD, Maarten H Vermeer iD und 3 weitere

British Journal of Haematology · 2026-07 · 209 (1) · 42-53

DOI: 10.1111/bjh.70562 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 25.05.2026. Verfasst von Sara Marchisio und 14 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunogenetics, Department of Medical Sciences, University of Turin, Turin, Italy. Hauptthemen laut MEDLINE: Sezary Syndrome, 5'-Nucleotidase, Antigens, CD, Apyrase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Projects of National Relevant Interest, IMMUNO-CANCER-PRIN-2021, KWF Dutch Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sézary syndrome (SS) is an aggressive cutaneous T‐cell lymphoma, characterized by erythroderma, lymphadenopathy and circulating malignant CD4 + T cells. Despite therapeutic advances, SS remains an incurable disease. Early diagnosis is therefore essential for timely therapeutic intervention; however, reliable biomarkers to identify circulating SS cells are still lacking. Recent studies highlighted dysregulation of the ectoenzymes CD39, CD73 and CD38 in SS, suggesting a potential role for these molecules in the disease. Thirty‐three patients were enrolled in this study, and CD39/CD73/CD38 expression was analysed on circulating CD4 + T cells by multiparametric flow cytometry, enabling discrimination between malignant and non‐malignant T‐cell subsets. SS cells exhibited marked CD39 or CD73 overexpression together with consistent CD38 downregulation, a pattern also confirmed in paired skin biopsy, whereas non‐malignant CD4 + T cells largely maintained expression profiles comparable to healthy controls. Genotyping further identified ENTPD1 single nucleotide polymorphism rs10748643 as a contributor to CD39 dysregulation, defining a CD39‐permissive subgroup characterized by CD39 + SS cells. In conclusion, the combined overexpression of CD39 or CD73 and loss of CD38 defines a distinct tumour‐restricted immunophenotypic signature in SS. Integrating these ectoenzymes into flow cytometry panels may improve detection of malignant CD4 + T cells across blood and skin, eventually strengthening diagnostic accuracy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sezary Syndrome5'-NucleotidaseAntigens, CDApyraseADP-ribosyl Cyclase 1Skin NeoplasmsBiomarkers, TumorHumansGPI-Linked ProteinsFemaleMaleMiddle AgedAgedFlow CytometryCD4-Positive T-LymphocytesAged, 80 and overPolymorphism, Single NucleotideMembrane Glycoproteins

Stichwörter der Autor:innen

CD38CD39CD73Sézary syndromeflow cytometrytumour markers

Substanzen

5'-NucleotidaseAntigens, CDApyraseGPI-Linked ProteinsADP-ribosyl Cyclase 1Biomarkers, TumorENTPD1 protein, humanCD39 antigenNT5E protein, humanCD38 protein, human

Autor:innen und Institutionen

  • Laboratory of Immunogenetics, Department of Medical Sciences, University of Turin, Turin, Italy.
  • Department of Neuroscience 'Rita Levi Montalcini', University of Turin, Turin, Italy.
  • Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.
  • Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands.
  • Interdipartimental Center for Molecular Biotechnologies 'Guido Tarone', University of Turin, Turin, Italy.

ORCID-Profile: Sara Marchisio, Yuliya Yakymiv, Liyun Lin, Erika Ortolan, Verdiana Pullano, Fenna J de Bie, Willem H Zoutman, Valentina Pala, Ferenc A Scheeren, Maarten H Vermeer, Ada Funaro, Pietro Quaglino, Gabriele Roccuzzo

Förderung

  • Research Projects of National Relevant Interest
  • IMMUNO-CANCER-PRIN-2021
  • KWF Dutch Cancer Society

Zitieren

APA

Marchisio, S., Yakymiv, Y., Lin, L., Ortolan, E., Pullano, V., Ponti, R., de Bie, F. J., van der Sluijs-Gelling, A. J., Zoutman, W. H., Pala, V., Scheeren, F. A., Vermeer, M. H., Funaro, A., Quaglino, P., & Roccuzzo, G. (2026). Utility of combined CD39 / CD73 / CD38 expression for the detection of malignant T cells in Sézary syndrome. British Journal of Haematology, 209(1), 42-53. https://doi.org/10.1111/bjh.70562

Vancouver

Marchisio S, Yakymiv Y, Lin L, Ortolan E, Pullano V, Ponti R, et al. Utility of combined CD39 / CD73 / CD38 expression for the detection of malignant T cells in Sézary syndrome. British Journal of Haematology. 2026;209(1):42-53. doi:10.1111/bjh.70562

BibTeX
@article{Marchisio2026,
  author = {Marchisio, Sara and Yakymiv, Yuliya and Lin, Liyun and Ortolan, Erika and Pullano, Verdiana and Ponti, Renata and de Bie, Fenna J and van der Sluijs-Gelling, Alita J and Zoutman, Willem H and Pala, Valentina and Scheeren, Ferenc A and Vermeer, Maarten H and Funaro, Ada and Quaglino, Pietro and Roccuzzo, Gabriele},
  title = {Utility of combined CD39 / CD73 / CD38 expression for the detection of malignant T cells in Sézary syndrome},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {209},
  number = {1},
  pages = {42--53},
  doi = {10.1111/bjh.70562}
}
Kostenlos starten →